MedTrace Logo

Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder

NCT00916786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2021-09-02

No results posted yet for this study

Summary

The ultimate goal of this study is to find the association between specific polymorphism of candidate genes and medication response in attention deficit hyperactivity disorder (ADHD) patients. These results will lead the investigators' team: (1) to resolve controversies over inconsistent findings in previous pharmacogenetic studies; (2) to study the medication effect on the neuropsychological functions that are useful candidate endophenotypes for ADHD; (3) to delineate the nature and the effect of gene-gene interaction in the drug response of ADHD patients.

Conditions

  • Attention Deficit Hyperactivity Disorder

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chi-Yung Shang, MD · Dept of Psychiatry, National Taiwan University Hospital

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-01
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916786 on ClinicalTrials.gov